Unveiling the influence of tumor and immune signatures on immune checkpoint therapy in advanced lung cancer

Nayoung Kim,Sehhoon Park,Areum Jo,Hye Hyeon Eum,Hong Kwan Kim,Kyungjong Lee,Jong Ho Cho,Bo Mi Ku,Hyun Ae Jung,Jong-Mu Sun,Se-Hoon Lee,Jin Seok Ahn,Jung-Il Lee,Jung Won Choi,Dasom Jeong,Minsu Na,Huiram Kang,Jeong Yeon Kim,Jung Kyoon Choi,Hae-Ock Lee,Myung-Ju Ahn

DOI: https://doi.org/10.1101/2024.04.15.589544

2024-04-20

Abstract:This study investigates the variability among patients with non-small cell lung cancer (NSCLC) in their responses to immune checkpoint inhibitors (ICI). Recognizing that patients with advanced-stage NSCLC rarely qualify for surgical interventions, it becomes crucial to identify biomarkers that influence responses to ICI therapy. We conducted an analysis of single-cell transcriptomes from 33 lung cancer biopsy samples, with a particular focus on 14 core samples taken before the initiation of palliative ICI treatment. Our objective was to link tumor and immune cell profiles with patient responses to ICI. We discovered that ICI non-responders exhibited a higher presence of CD4+ regulatory T cells, resident memory T cells, and TH17 cells. This contrasts with the diverse activated CD8+ T cells found in responders. Furthermore, tumor cells in non-responders frequently showed heightened transcriptional activity in the NF-kB and STAT3 pathways, suggesting a potential inherent resistance to ICI therapy. Through the integration of immune cell profiles and tumor molecular signatures, we achieved an accuracy rate exceeding 95% in predicting patient responses to ICI treatment. These results underscore the crucial importance of the interplay between tumor and immune microenvironment, including within metastatic sites, in affecting the effectiveness of ICIs in NSCLC.

Bioinformatics

What problem does this paper attempt to address?

The paper primarily explores the different responses of non-small cell lung cancer (NSCLC) patients to immune checkpoint inhibitors (ICI) treatment and attempts to reveal the impact of tumor and immune characteristics on the efficacy of ICI.

Specifically, the research team analyzed single-cell transcriptome data from 33 lung cancer biopsy samples, with a particular focus on 14 core samples obtained before the initiation of palliative ICI treatment. By comparing the differences between ICI responders and non-responders, the researchers found that non-responders had a higher proportion of CD4+ regulatory T cells, resident memory T cells, and TH17 cells, while responders exhibited a more diverse activation of CD8+ T cells. Additionally, in the tumor cells of non-responders, the transcriptional activities of the NF-kB and STAT3 signaling pathways were enhanced, which may indicate an intrinsic resistance of these cells to ICI treatment.

By integrating immune cell characteristics and tumor molecular markers, the research team constructed a predictive model that can predict patient response to ICI treatment with an accuracy of over 95%. This result emphasizes the importance of the interactions between tumor cells and immune cells in the tumor microenvironment, particularly in influencing the effectiveness of ICI in NSCLC.

In summary, this paper aims to identify key biomarkers that affect ICI treatment responsiveness through systematic tumor and immune cell analysis at single-cell resolution, providing a theoretical basis for future clinical applications.